1. Introduction {#s0005}
===============

Rheumatoid arthritis (RA) is a systemic inflammatory disorder and the most common inflammatory arthritis ([@b0065], [@b0005]). The incidence of RA in 2008 was estimated to be 42/100,000 in South Korea ([@b0125]). And the annual incidence in Norway was 28.7/100,000 ([@b0110]) and 44.6/100,000 in Rochester, Minnesota ([@b0030]).

RA is the most common autoimmune disease. The adaptive T-cell response interactions with environmental factors such as smoking lead to a systemic autoantibody response and it results in the synovial inflammatory process ([@b0095]). In these inflammatory responses, many previous studies investigated the role of genetic factors. HLA has been regarded as an important genetic factor in RA risk ([@b0090]). *IL27* gene polymorphism was associated with susceptibility of RA in Chinese ([@b0140]). Recent meta-analysis showed the association between *CCR6* polymorphism and RA ([@b0025]).

*IL4* gene is located at 5q31.1 and encodes interleukin 4 (<http://www.ncbi.nlm.nih.gov>). IL4 improves anti-inflammatory effect and suppresses several pro-inflammatory cytokines and systemic IL4 treatment protects the cartilage and bone destruction in established murine type II collagen-induced arthritis ([@b0050]). Also, IL4 could be used for the treatment of RA in association with anti-TNF alpha or anti-IL1 beta ([@b0075]). Genetic polymorphism of *IL4* also has an association with RA. *IL4* promoter polymorphism may be a genetic risk factor for RA severity ([@b0100]). Previous study also suggested that the promoter polymorphism may be helpful for assessing RA severity (joint erosion and anti-CCP) and TT genotype of polymorphism (−590) showed a significant decrease of IL4 level in serum ([@b0080]).

Though the roles of *IL4* polymorphisms in RA have been reported in Chinese ([@b0070]) or White participants, the results has been controversial. In this study, we performed a meta-analysis on all eligible case-control studies to clarify the association between *IL4* polymorphism (−590) and susceptibility to RA.

2. Materials and methods {#s0010}
========================

2.1. Search strategy and data extraction {#s0015}
----------------------------------------

We firstly found the meta-analysis studies between *IL4-590* polymorphism and RA. And electronic database including pubmed, embase, google of scholar, and Korean Studies Information Service System (KISS) were investigated up to June 2015. In order to select eligible studies about *IL4-590* polymorphism and RA. The keywords to find eligible studies were used: "interleukin 4", "IL4", or "cytokine", AND "polymorphism" or "SNP" AND "−590" or "rs2243250" AND "RA". The data of first author's name, year of publication, country, sample size of RA and control, genotype frequencies of *IL4-590* polymorphism in RA and control were extracted from the final selected studies.

2.2. Inclusion criteria {#s0020}
-----------------------

Studies were included if they met the following criteria: (1) evaluated the association between the IL4 polymorphism (−590, T/C) and RA; (2) used a case-control study design; (3) contained sufficient published data for the estimation of an odds ratio (OR) with a 95% confidence interval (CI).

2.3. Statistical analysis {#s0025}
-------------------------

Hardy--Weinberg equilibrium (HWE) in the control group of include studies was evaluated by the Chi-square test. Meta-analysis and sensitivity analysis were used by the Comprehensive Meta-analysis software (Corporation, NJ, USA). The pooled p value, OR, and 95% CI were used to assess the strength of association between risk of RA and *IL4-590* polymorphism ([@b0055], [@b0115]). The meta-analysis was performed while omitting each study one at a time to examine the influence of each study on the pooled OR. In order to assess heterogeneity among the studies, a *χ*^2^-test-based *Q* statistic test and *I* squared test were done. The random-effects Mantel--Haenszel method was adopted if the result of the *Q* test was *P* \< 0.05 or *I* squared value was \>50%, which indicated the statistically significant heterogeneity between the studies. Otherwise, the fixed-effects Mantel--Haenszel method was adopted. And Begg's funnel plot and Egger's test were performed to evaluate publication bias. For sensitivity analysis, the meta-analysis was performed subtracting each study to examine the influence of each study over and over again. The *P* \< 0.05 was regarded as statistically significant.

3. Results {#s0030}
==========

The present study performed the meta-analysis to assess relationship between promoter polymorphism (−590, T/C) of *IL4* gene and susceptibility of RA. Firstly, searching was conducted to find related studies from electronic databases according to search strategy. Eleven case and control studies about promoter polymorphism (−590, T/C) of *IL4* gene polymorphism (Ser326Cys) and susceptibility of RA were searched ([@b0015], [@b0020], [@b0035], [@b0045], [@b0070], [@b0085], [@b0080], [@b0100], [@b0105], [@b0135]). Among these studies, six studies ([@b0020], [@b0100], [@b0080], [@b0085], [@b0135], [@b0045]) were analyzed by meta-analysis in 2013 ([@b0120]). However, there was an error in data by the meta-analysis in 2013. [@b0120] reported results of meta-analysis between promoter polymorphism (−590, T/C) of *IL4* gene and susceptibility of RA. They included the data from the study ([@b0020]) in the meta-analysis They summarized that the genotype frequencies (C/C:C/T:T/T) of promoter polymorphism (−590, T/C) of *IL4* gene in the control group were 32:36:0, but original data of the study ([@b0020]) is 82:36:0. In meta-analysis between specific polymorphisms and susceptibility of diseases, it was important to search eligible studies and extract exact data. So, this updated meta-analysis was performed.

[Table 1](#t0005){ref-type="table"} shows characteristics of eligible studies included in the meta-analysis. The first author's name, year of publication, country, sample size, and genotype frequencies of *IL4*-590 polymorphism in RA patients and controls were extracted. Among eleven studies, studies by [@b0135], [@b0015] were excluded in the meta-analysis because HWEs of genotype distribution of *IL4*-590 polymorphism in the control group was *p* \< 0.05. [Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"} presents the results of meta-analysis between *IL4*-590 polymorphism and susceptibility of RA in nine studies. In all models, *IL4*-590 polymorphism revealed the significant association with susceptibility of RA (random model, OR = 1.303, 95% CI = 1.093--1.554, *P* = 0.003 in allele; random model, OR = 1.247, 95% CI = 1.054--1.474, *P* = 0.010 in dominant; random model, OR = 2.148, 95% CI = 1.263--3.651, *P* = 0.005 in recessive; Fixed model, OR = 1.128, 95% CI = 1.025--1.241, *P* = 0.014 in codominant 1; Random model, OR = 2.272, 95% CI = 1.313--3.931, *P* = 0.003 in codominant 2). Sensitivity analysis confirmed the stability of the results of meta-analysis (data not shown) and no publication bias was found in the present meta-analysis. These results indicate that promoter polymorphism (−590, T/C) of *IL4* gene polymorphism is related to susceptibility of RA ([Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}).

4. Discussion {#s0035}
=============

Many factors such as gene, cytokine, inflammatory mediators, adhesion molecules, and so on involve in the pathophysiology of RA. Among them, many genetic factors have been identified due to advances in genetic methods ([@b0065]). In this study, we focused on the genetic factor of RA and carried out meta-analysis to investigate the relation between *IL4* polymorphism and the risk of developing RA.

In the present study, we could find significant associations in allele, dominant, and recessive models. The results of this meta-analysis are consistent with the results of a previous meta-analysis ([@b0015]). Among these, only the study by [@b0070] involves Asian population (Chinese). According to NCBI database, genotype frequency in Chinese is 0.023 (C/C), 0.395 (C/T), and 0.581 (T/T) and allele frequency in Chinese is 0.221 (C) and 0.779 (T). On the other hand, genotype and allele frequencies in White are definitely different. According to NCBI database, genotype frequency in European is 0.743 (C/C), 0.239 (C/T), and 0.018 (T/T) and allele frequency in Chinese is 0.863 (C) and 0.137 (T). As shown in [Table 1](#t0005){ref-type="table"}, genotype and allele frequencies in previous studies are similar to those in NCBI database. Interestingly, the genotypes and allele frequencies in 2014 by [@b0070] are similar to those of European rather than those of Asian according to NCBI database. Previous study reported that the incidence and prevalence of RA showed different trends according to ethnicity. In Korea, the prevalence of RA in 2008 was estimated to be 0.27% ([@b0125]). One study on rural African had found only 14 cases of RA in about 520,000. The prevalence of RA was 0.0026% ([@b0010]). In contrast, the prevalence of RA in a Chippewa Band (American Indian) reached to 5.3--6.8% ([@b0040]). A study in Norway reported that the prevalence of RA was 0.47% in 1994 ([@b0110]). In United Kingdom, the prevalence of RA is 1.16% in women and 0.44% in men ([@b0130]). The prevalence of RA in the urbanized Chinese of Hong Kong was 0.35% ([@b0060]). Thus, previous studies showed the significant geographic variations of RA occurrence and difference of prevalence according to ethnicity. These results suggest an association of RA with ethnicity and genetic factors.

5. Conclusion {#s0040}
=============

In conclusion, our meta-analysis study showed that *IL4* polymorphism was associated with RA. However, the limitation of our study is that there was not enough data on other ethnicities. We could not find the studies on African population and the number of studies on Asian was only one. In spite of these limitation, our meta-analysis provided evidence of the association between *IL4* polymorphism and risk of RA. It is well known that early diagnosis and treatment of RA could lead to favorable outcomes. Therefore, early diagnosis and preventive treatment by detecting the susceptibility to RA in gene level would play a major role in improving the prognosis of RA. Many previous association studies revealed the association between *IL4* polymorphism and RA and our present meta-analysis strengthened the relationship. If further studies will be performed in more population, promoter polymorphism (−590, T/C) of *IL4* gene could be a useful marker for the early diagnosis and treatment of RA.

Author disclosure statement {#s0045}
===========================

No competing financial interests exist.

This work was supported by a Grant from Kyung Hee University in 2010 (KHU-20101896).

Peer review under responsibility of King Saud University.
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###### 

Characteristics of eligible studies included in the meta-analysis.

  Study      Country         RA/Control (*n*)   Genotyping method   RA    Control   RA   Control   HWE in control                                  
  ---------- --------------- ------------------ ------------------- ----- --------- ---- --------- ---------------- ---- ------ ----- ------ ----- -------------
  [@b0135]   Macedonia       85/286             Sequencing          47    37        1    95        187              4    131    39    377    195   **\<0.001**
  [@b0085]   Spain           599/540            TaqMan              398   179       22   375       155              10   975    223   905    175   0.185
  [@b0080]   Colombian       102/102            PCR-RFLP            39    48        15   49        48               5    126    78    146    58    0.11
  [@b0100]   Poland          94/102             PCR-RFLP            62    28        4    74        26               2    152    36    174    30    0.87
  [@b0105]   Sweden          1503/875           Sequenom            940   507       56   584       253              38   2387   619   1421   329   0.12
  [@b0105]   North America   835/847            Sequenom            594   219       22   571       254              22   1407   263   1396   298   0.38
  [@b0020]   France          107/68             PCR-RFLP            63    41        3    82        36               0    167    47    200    36    0.05
  [@b0035]   Netherland      372/460            Sequencing          267   91        14   339       112              9    625    119   790    130   0.94
  [@b0045]   Egypt           172/172            PCR-RFLP            96    56        20   123       46               3    248    96    292    52    0.58
  [@b0070]   China           752/798            PCR-RFLP            481   218       53   575       207              16   1180   324   1357   239   0.60
  [@b0015]   Spain           1239/1229          KASPar              859   325       34   863       275              34   2043   393   2001   343   **0.037**

RA = rheumatoid arthritis, *n* = number of subjects.

Bold number indicates significant difference.

###### 

Overall analysis between *IL4*-590 polymorphism and susceptibility of RA in nine studies.

  Genetic comparison   Association            Heterogeneity   Model     Publication bias            
  -------------------- ---------------------- --------------- --------- ------------------ -------- ------
  C vs. T              1.303 (1.093--1.554)   **0.003**       \<0.001   75.46              Random   0.18
  C/C vs. C/T + T/T    1.247 (1.054--1.474)   **0.010**       0.006     62.75              Random   0.22
  C/C + C/T vs. T/T    2.148 (1.263--3.651)   **0.005**       \<0.001   72.26              Random   0.09
  C/C vs. C/T          1.128 (1.025--1.241)   **0.014**       0.100     40.28              Fixed    0.37
  C/C vs. T/T          2.272 (1.313--3.931)   **0.003**       \<0.001   73.55              Random   0.10

Rheumatoid arthritis (RA), odds ratio (OR), confidence interval (CI), number of subjects (*n*).

Bold numbers indicate significant association with RA.
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